Tirzepatide vs. Retatrutide
Today's Champion vs. The Next-Generation Triple Agonist
Tirzepatide (GLP-1 + GIP) is FDA approved and produces ~20% weight loss. Retatrutide adds glucagon receptor agonism — a third mechanism that showed 24.2% weight loss in Phase 2, plus extraordinary liver fat reduction. Here is the full comparison of what you can take today versus what is coming.
Tirzepatide: GLP-1 + GIP Dual Agonist
Tirzepatide was the first dual incretin agonist — hitting both GLP-1 and GIP receptors simultaneously. GLP-1 suppresses appetite and slows gastric emptying; GIP acts on fat cells and the brain to further reduce food intake and promote energy expenditure. The combination produces more weight loss than any single-agonist GLP-1 drug and earned FDA approval for both type 2 diabetes (Mounjaro) and obesity (Zepbound), plus obstructive sleep apnea.
Retatrutide: GLP-1 + GIP + Glucagon Triple Agonist
Retatrutide adds glucagon receptor agonism to the GLP-1/GIP base. Glucagon agonism increases thermogenesis (raises resting metabolic rate), drives hepatic fat oxidation (directly reducing liver fat), and may sustain weight loss by preventing the metabolic adaptation that slows weight loss on other GLP-1 drugs. This is why retatrutide Phase 2 data showed the largest weight loss ever recorded in an obesity trial.
Full Comparison: Tirzepatide vs Retatrutide
Who Should Choose Which?
Use Tirzepatide Now If…
- ✓You have obesity, T2D, or obstructive sleep apnea and need FDA-approved treatment available today.
- ✓You want proven Phase 3 data, not Phase 2 results — tirzepatide has SURMOUNT-1 through -4, with 20%+ weight loss confirmed across large trials.
- ✓You have liver disease (MASH/MASLD) — tirzepatide already has strong hepatic fat reduction data (SURMOUNT-NASH trial).
- ✓You can access it through insurance, a manufacturer coupon program, or compounding pharmacy at lower cost.
Watch Retatrutide If…
- ✓You have severe MASH or advanced metabolic fatty liver disease and the hepatic glucagon mechanism is specifically important to you.
- ✓You have plateaued on tirzepatide at max dose and want to understand what options may exist when retatrutide becomes available.
- ✓You are interested in a thermogenic mechanism — the glucagon-driven increase in resting metabolic rate is a genuinely novel benefit not available in current GLP-1 drugs.
- ✓You are in or eligible for the TRIUMPH Phase 3 trials and want access to cutting-edge data.
FAQ
What makes retatrutide different from tirzepatide?
Both drugs agonize GLP-1 and GIP receptors — the same two targets as tirzepatide (Mounjaro/Zepbound). Retatrutide adds a third target: the glucagon receptor. Glucagon receptor agonism has two effects that pure GLP-1/GIP drugs lack. First, it is thermogenic — it raises basal metabolic rate by increasing hepatic glucose and fat oxidation. Second, it directly drives liver fat reduction, making it exceptionally powerful for MASLD/MASH (metabolic fatty liver disease). Phase 2 data showed 24.2% weight loss at 48 weeks — the largest weight reduction ever seen in a Phase 2 obesity trial.
Is retatrutide FDA approved?
As of early 2026, retatrutide is not yet FDA approved. Eli Lilly's Phase 3 TRIUMPH program is underway, with efficacy data expected in 2025–2026. FDA approval could follow in 2026–2027 if Phase 3 confirms Phase 2 results. Tirzepatide (as Zepbound and Mounjaro) is fully approved today for obesity and type 2 diabetes, with an additional approval for obstructive sleep apnea.
Should I wait for retatrutide instead of starting tirzepatide?
That depends on your situation. If you have obesity with metabolic liver disease (MASLD/MASH), retatrutide's glucagon-driven hepatic fat reduction is a compelling reason to watch Phase 3 data closely. If you need treatment now, tirzepatide produces ~20% weight loss with a well-established safety profile and is FDA approved. For most people, the benefits of starting tirzepatide today outweigh waiting 1–2 years for a drug that may produce an additional ~4% weight loss. You can always switch if retatrutide is approved.
Track Tirzepatide — And Switch When Ready
Shotlee supports tirzepatide tracking today — weekly injection logs, dose escalation timelines, and weight trends. When retatrutide arrives, your history will carry over seamlessly.
Download Shotlee Free